Arbutus Biopharma (ABUS) Non Operating Investment Income (2018)
Arbutus Biopharma (ABUS) posted quarterly Non Operating Investment Income of $24.9 million for Q2 2018.
Arbutus Biopharma (ABUS) Non Operating Investment Income (2018) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Non Operating Investment Income for 1 consecutive years, with $24.9 million the latest figure, recorded in Q2 2018.
- Quarterly Non Operating Investment Income changed N/A year-over-year to $24.9 million in Q2 2018, while the trailing twelve-month figure through Jun 2019 was $24.9 million (changed 0.0% YoY) and the FY2018 annual result came in at $24.9 million, changed N/A from the prior year.
- Non Operating Investment Income held at $24.9 million in Q2 2018 per ABUS's latest filing.
- Over the last five years, Non Operating Investment Income for ABUS reached as high as $24.9 million in Q2 2018 and fell as low as $24.9 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Arbutus Biopharma | 862.27 Mn | 767.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 24.88 Mn |
| Jun 30, 2018 | 24.88 Mn |